Shoulder Replacement and Reverse Shoulder Arthroplasty

Shoulder replacement surgery encompasses two distinct prosthetic approaches — anatomic total shoulder arthroplasty and reverse shoulder arthroplasty — each designed for different patterns of joint failure and rotator cuff integrity. This page covers the mechanical principles behind each implant design, the clinical scenarios that drive procedure selection, and the decision boundaries surgeons apply when recommending one approach over the other. Understanding these distinctions is relevant to anyone navigating a diagnosis of advanced shoulder pathology and seeking an accurate frame of reference for the treatment landscape.

Definition and Scope

Shoulder arthroplasty is the surgical replacement of the glenohumeral joint — the ball-and-socket articulation between the humeral head and the glenoid face of the scapula. The procedure falls under the broader orthopedic category of joint replacement, which the American Academy of Orthopaedic Surgeons (AAOS) classifies alongside hip and knee arthroplasty as a high-volume reconstructive intervention.

Two primary implant configurations are recognized:

Anatomic Total Shoulder Arthroplasty (aTSA) — replaces the humeral head with a metal ball component and resurfaces the glenoid with a polyethylene cup, replicating the native joint geometry.
Reverse Total Shoulder Arthroplasty (rTSA) — inverts the ball-and-socket relationship by placing the glenoid ball (glenosphere) on the scapula and the socket on the humeral stem, fundamentally altering the joint's biomechanics to compensate for rotator cuff deficiency.

A third, more limited option — hemiarthroplasty — replaces only the humeral head without resurfacing the glenoid, typically reserved for specific fracture patterns or younger patients with isolated humeral pathology.

The AAOS has reported that shoulder arthroplasty is performed approximately 53,000 times per year in the United States (AAOS OrthoInfo), making it the third most common joint replacement procedure after hip and knee. Implant components are regulated as Class III medical devices by the U.S. Food and Drug Administration (FDA), subject to premarket approval (PMA) requirements under 21 CFR Part 814.

For broader regulatory framing governing orthopedic procedures and implant oversight, the regulatory-context-for-orthopedics section of this resource covers the relevant agency and statutory landscape in detail.

How It Works

Anatomic Total Shoulder Arthroplasty

In aTSA, the surgeon removes the arthritic humeral head and prepares the humeral canal to receive a stemmed or stemless metal implant. The glenoid surface is reamed and fitted with a polyethylene component. The reconstructed joint relies on intact rotator cuff tendons — specifically the subscapularis, supraspinatus, and infraspinatus — to provide dynamic stability and power through the range of motion. Without a functioning rotator cuff, the polyethylene glenoid component is susceptible to eccentric loading, a failure pattern termed "rocking horse glenoid loosening."

Reverse Total Shoulder Arthroplasty

In rTSA, the biomechanical logic shifts entirely. The glenosphere attached to the scapula acts as the fixed ball, and the polyethylene cup on the humeral component articulates against it. This configuration moves the center of rotation medially and inferiorly, lengthening the moment arm of the deltoid muscle. The deltoid then assumes primary responsibility for arm elevation — a function that would otherwise require an intact rotator cuff. The design was pioneered by French orthopedic surgeon Paul Grammont in the 1980s, and the Grammont-style prosthesis remains the foundational reference for contemporary rTSA implants.

Both procedures are performed under general or regional anesthesia through a deltopectoral or superior approach. Soft tissue repair, particularly of the subscapularis tendon, is a discrete surgical step that influences postoperative stability and rehabilitation trajectory. The rehabilitation-after-orthopedic-surgery protocol for shoulder arthroplasty typically spans 4 to 6 months before full functional recovery is expected.

Common Scenarios

The clinical contexts that lead to shoulder arthroplasty are distinct for each implant type.

Anatomic TSA is indicated in:

End-stage glenohumeral osteoarthritis with a concentric glenoid and intact rotator cuff (the most common indication)
Rheumatoid arthritis affecting the glenohumeral joint without massive cuff tearing
Post-traumatic arthritis with preserved cuff function
Avascular necrosis of the humeral head at advanced stages

Reverse TSA is indicated in:

Cuff tear arthropathy — a pattern of glenohumeral arthritis caused by a massive, irreparable rotator cuff tear, first systematically described by Charles Neer II
Failed prior anatomic shoulder replacement complicated by rotator cuff failure
Complex proximal humerus fractures in older patients (typically older than 70) where fracture fixation carries high failure risk
Irreparable rotator cuff tears without significant arthritis (in select cases)
Revision of failed hemiarthroplasty

Rotator cuff pathology is central to scenario classification. For patients whose shoulder problems originate from a cuff tear rather than arthritis, the distinction between a repairable and an irreparable tear is a threshold decision that precedes arthroplasty consideration. The rotator-cuff-tears-shoulder-injuries reference covers tear classification and repair candidacy in detail.

Decision Boundaries

Surgeons apply a structured set of criteria to determine which procedure — or whether any arthroplasty — is appropriate. The decision is not binary; it incorporates imaging findings, functional deficits, patient age, bone stock, and prior surgical history.

Primary decision criteria:

Rotator cuff integrity — Intact or repairable cuff favors aTSA. Massive, irreparable tear mandates rTSA.
Glenoid bone stock — Severe glenoid erosion (Walch Type B2 or C classification on CT) may preclude stable glenoid component seating in aTSA and shift the plan toward rTSA or augmented implants.
Patient age — The longevity of polyethylene glenoid components in aTSA is a concern in patients younger than 55, given that revision procedures carry higher complexity. The AAOS has documented that younger patients face statistically higher lifetime revision risk.
Active elevation — Loss of active forward flexion below 90 degrees in the setting of a rotator cuff tear is a functional threshold that commonly supports rTSA candidacy.
Prior surgical history — Failed arthroplasty components, particularly loose glenoid components from aTSA, typically convert to rTSA at revision, a technically demanding procedure with increased complication rates.

The total-hip-replacement and total-knee-replacement pages offer parallel decision frameworks for lower-extremity arthroplasty that share structural similarities with shoulder replacement candidacy evaluation.

The FDA's Orthopaedic Devices Panel monitors postmarket safety signals for shoulder implants, and surgeons in the United States are required to register implant use through hospital systems that feed into device surveillance registries. The American Shoulder and Elbow Surgeons (ASES) maintains specialty-specific outcome standards and outcome scoring instruments — including the ASES shoulder score — that are used in both clinical trials and postoperative assessment. For a comprehensive entry point into orthopedic subspecialties and care pathways, the index provides a structured overview of the full resource.

Patients evaluated for shoulder arthroplasty typically undergo plain radiography, CT scanning for glenoid morphology assessment, and MRI evaluation of rotator cuff integrity before a final implant selection is made — a sequence that reflects both clinical best practice and the imaging requirements documented in surgical planning literature published by the ASES and AAOS.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)